Matthew A. Lunning

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

Medicine, Oncology, Pharmacology +13

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

Medicine, Hematology, Oncology +17

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson, Bryan J. Schneider, Julie R. Brahmer et al. · Journal of the National Comprehensive Cancer Network · 2019 · 560 citations · Full text

Medicine, Oncology, Oncology Nursing +17

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

John A. Thompson, Bryan J. Schneider, Julie R. Brahmer et al. · Journal of the National Comprehensive Cancer Network · 2020 · 486 citations · Full text

Medicine, Immunology, Oncology +17